The same AI systems that can design life-saving drugs can, in theory, design the opposite. Anthropic, OpenAI, and Google DeepMind have decided to get ahead of that problem before it becomes a crisis.
The three dominant AI labs are rolling out a suite of safety measures targeting biological applications of their models, from drug discovery and disease research to pandemic preparedness. The coordinated push includes real-time content classifiers, vetted researcher access programs, and extensive red teaming, all designed to let the good science through while slamming the door on bioweapons research.
A public letter and a line in the sand
In June 2026, the CEOs of all three companies signed a public letter directed at US lawmakers. The message was blunt: synthetic DNA and RNA providers need mandatory screening and recordkeeping requirements, because AI is making it significantly easier to design dangerous biological agents.
Google DeepMind moved first on a concrete program. On July 16, the company announced its bioresilience initiative, which pairs trusted researchers with rapid-deployment drug design engines. DeepMind’s approach leans heavily on its Isomorphic Labs subsidiary, which has been building AI systems specifically for drug discovery. The bioresilience program extends that work into defensive territory, focusing on counteracting biological threats rather than just finding new medicines.
Anthropic’s balancing act
Anthropic, for its part, has been wrestling with one of the trickiest problems in AI safety: how to stop dangerous queries without blocking legitimate science. In August 2026, the company announced it had reduced false-positive blocks on benign biology queries by roughly 85%.
But Anthropic didn’t loosen everything. Professional workflows tied to drug development still face tighter restrictions, reflecting the company’s judgment that the most sophisticated biological queries carry the highest dual-use risk.
This calibration sits at the heart of Anthropic’s Responsible Scaling Policy, a framework the company has been developing to govern how its models interact with sensitive domains. The policy establishes escalating safety requirements as models become more capable, with CBRN (chemical, biological, radiological, nuclear) thresholds serving as hard lines that trigger additional review.
OpenAI has taken a parallel track with its Preparedness Framework, launched in 2025. That framework encompasses biodefense initiatives and drug success prediction tools, essentially trying to make AI useful for pharmaceutical development while maintaining guardrails against misuse.